Risk factors of Helicobacter pylori infection in an urban community in Northeast Brazil and the relationship between the infection and gastric diseases
Helicobacter pylori is the primary etiologic agent involved in gastric diseases in humans with worldwide distributions. In
2005, H. pylori was identified as a microbiologic contaminant of water, and its role in gastric diseases was further assessed.
IMMUNODETECTION OF PEPSINOGENS, GASTRIN-17 AND HELICOBACTER PYLORI FOR NON-INVASIVE DIAGNOSIS OF HIGH-RISK ATROPHIC GASTRITIS IN CHILE
astric cancer is one of the most common types of cancer in the world. In Chile, the disease represents the first cause of cancer death in men and the third cause in women, where approximately 3000 individuals died every year from gastric cancer.
Helicobacter pylori treatment effectiveness in developing countries: A network meta-analysis
Helicobacter pylori is a putative risk factor for peptic ulcers and gastric cancer. Current treatment guidelines for H pylori are based on results from developed countries.
Plasma levels of soluble Urokinase Plasminogen Activator Receptor and Pepsinogen I/II ratios as gastric cancer biomarkers in Guatemalan patients
In Guatemala, gastric cancer (GC) presents some of the highest rates of incidence and mortality in the world.
Disparities in Gastric Cancer epidemiological profile in three Brazilian cities (Belem, Fortaleza and Sao Paulo)
Despite decreasing global incidence trends, gastric cancer is still among the five most incident cancers in the world and the third cancer-related cause of death.
Metabolite concentrations and H. pylori risk in GC cases and FDR controls
Serum pepsinogen 2 (sPG2) level is one of the predictive parameters for gastric cancer (GC) risk but factors that regulate change in PG2 expression are still unknown. Aim of the present study was to investigate genetic variants that may regulated PG2 expression in patients with GC or at risk for GC.